UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Leukemia, 2009-07, Vol.23 (7), p.1337-1341

2009

Volltextzugriff (PDF)

Exchange bias effect and glassy-like behavior of EuCrO3 and CeCrO3 nano-powders

Journal of applied physics, 2015-09, Vol.118 (12)

2015

Volltextzugriff (PDF)

Nondiffractive subwavelength wave beams in a medium with externally controlled anisotropy

Physical review letters, 2010-05, Vol.104 (19), p.197203-197203, Article 197203

2010

Volltextzugriff (PDF)

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

Bone marrow transplantation (Basingstoke), 2015-02, Vol.50 (2), p.204-208

2015

Volltextzugriff (PDF)

Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma

Leukemia, 2009-03, Vol.23 (3), p.585-590

2009

Volltextzugriff (PDF)

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Leukemia, 2013-12, Vol.27 (12), p.2351-2356

2013

Volltextzugriff (PDF)

Water-dispersible and ferroelectric PEGylated barium titanate nanoparticles

Materials advances, 2021-08, Vol.2 (15), p.589-595

2021

Volltextzugriff (PDF)

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

Bone marrow transplantation (Basingstoke), 2015-01, Vol.50 (1), p.95-99

2015

Volltextzugriff (PDF)

Shape-controlled MnO nanoparticles as T1 MRI contrast agents

AIP advances, 2019-12, Vol.9 (12), p.125031-125031-5

2019

Volltextzugriff (PDF)

CyBorD induction therapy in clinical practice

Bone marrow transplantation (Basingstoke), 2015-03, Vol.50 (3), p.375-379

2015

Volltextzugriff (PDF)

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

HemaSphere, 2022-06, Vol.6 (Suppl), p.852-853

2022

Volltextzugriff (PDF)

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB‐CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1905-1906

2022

Volltextzugriff (PDF)

Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7069-7073

2005

Volltextzugriff (PDF)

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

HemaSphere, 2023-05, Vol.7 (S2), p.27-28

2023

Volltextzugriff (PDF)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.788-789

2022

Volltextzugriff (PDF)

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐4 STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.830-831

2022

Volltextzugriff (PDF)

Turnover and fractionation of carbon and nitrogen stable isotopes in tissues of a migratory coastal predator, summer flounder (Paralichthys dentatus)

Canadian journal of fisheries and aquatic sciences, 2010-03, Vol.67 (3), p.445-461

2010

Volltextzugriff (PDF)

P13: CAN PATIENT‐REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

HemaSphere, 2022-04, Vol.6 (Suppl), p.18-18

2022

Volltextzugriff (PDF)

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S195-S196

2021

Volltextzugriff (PDF)

Photochemical Route for the Preparation of Complex Amorphous Water Oxidation Catalyst

ECS transactions, 2014-04, Vol.58 (45), p.67-76

2014

Volltextzugriff (PDF)

Improving the colloidal stability of PEGylated BaTiO3 nanoparticles with surfactants

Chemical physics, 2023-01, Vol.564, p.111701, Article 111701

2023

Volltextzugriff (PDF)

Tissue-specific isotope trophic discrimination factors and turnover rates in a marine elasmobranch: empirical and modeling results

Canadian journal of fisheries and aquatic sciences, 2012-03, Vol.69 (3), p.551-564

2012

Volltextzugriff (PDF)

Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway

Cell death and differentiation, 2007-03, Vol.14 (3), p.511-523

2007

Volltextzugriff (PDF)

A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e298-e298

2015

Volltextzugriff (PDF)

Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e139-e139

2015

Volltextzugriff (PDF)

1 – 25 von 3.990

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.018)
Mit Volltextzugriff
(3.162)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.429)
Life Sciences & Biomedicine
(1.084)
Humans
(653)
Male
(381)
Animals
(377)
Female
(361)
Biological And Medical Sciences
(359)
Physical Sciences
(249)
Technology
(238)
Middle Aged
(220)
Adult
(214)
Social Sciences
(203)
Medical Sciences
(190)
Fundamental And Applied Biological Sciences. Psychology
(180)
Aged
(176)
Mice
(143)
Oncology
(141)
Biochemistry & Molecular Biology
(137)
Engineering
(124)
Psychology
(120)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Exchange bias effect and glassy-like behavior of EuCrO3 and CeCrO3 nano-powders

Nondiffractive subwavelength wave beams in a medium with externally controlled anisotropy

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Water-dispersible and ferroelectric PEGylated barium titanate nanoparticles

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

Shape-controlled MnO nanoparticles as T1 MRI contrast agents

CyBorD induction therapy in clinical practice

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB‐CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

P31 SINGLE‐AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM‐2 TRIAL

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM‐4 STUDY

Turnover and fractionation of carbon and nitrogen stable isotopes in tissues of a migratory coastal predator, summer flounder (Paralichthys dentatus)

P13: CAN PATIENT‐REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Photochemical Route for the Preparation of Complex Amorphous Water Oxidation Catalyst

Improving the colloidal stability of PEGylated BaTiO3 nanoparticles with surfactants

Tissue-specific isotope trophic discrimination factors and turnover rates in a marine elasmobranch: empirical and modeling results

Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway

A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)

Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients

Suchergebnisse filtern